

Serial No. 10/721,537

from Resindoin SRL, Milan, Italy, and DOWEX 2 from the Dow Chemical Co., Midland, Mich. The invention is not limited to the use of these particular products, however.

In an alternate embodiment, the extract of the invention can be obtained by treatment of commercially available *Tanacetum parthenium* extracts produced in the conventional manner with strongly basic resins. Optionally, lipophilic components which could adversely interfere with the resin may first be extracted with the use of hydrocarbon solvents before treatment with the resins.

Since the  $\alpha$ -unsaturated  $\gamma$ -lactones cause some of the allergic reactions to extracts of feverfew, topical compositions made from  $\alpha$ -unsaturated  $\gamma$ -lactone-deprived extracts are expected to be non-irritating.

Please delete the figure 1 in Page 13.

MAP  
3-1/07 Please add the following Paragraph on page ~~5~~<sup>2</sup>, line 28.

**BRIEF DESCRIPTION OF THE DRAWING**

Figure 1 shows effect of parthenolide-free feverfew on PGE-2 production